Performance
Revenue ($m)
$2,553mOperating profit ($m)
$582mCore¹ operating profit ($m)
$632mEBITDA² ($m)
$727mProfit to shareholders ($m)
$421mBasic earnings per share³ (cents)
182cCore basic earnings per share³ (cents)
195cDividend per share (cents)
54c- Core results are presented to show the underlying performance of the Group, excluding the exceptional items and other adjustments set out in Note 6 of the Group consolidated financial statements
- EBITDA is earnings before interest, tax, depreciation, amortisation, asset write-down and impairment charges
- In June 2020, Hikma purchased 12.8 million ordinary shares from Boehringer Ingelheim,
which are being held in treasury
Interim results 2022
Watch full video - Interim results 2022
Key financial highlights from Said Darwazah, Chairman and CEO
Key financial highlights from Khalid Nabilsi, Chief Financial Officer
Key financial highlights from Riad Mishlawi, President, Injectables
Key financial highlights from Mazen Darwazah, Executive Vice Chairman and President, MENA video
Key financial highlights from Brian Hoffmann, President Generics
Four reasons to invest in Hikma
We have a strong business model with significant opportunities to further enhance our portfolio to drive growth and deliver value for shareholders.
1Solid platform for growth
- Broad portfolio of over 670 high-quality products across three businesses
- Agile supply chain, flexible manufacturing and leading technical capabilities
- Leading supplier of both generic injectable and non-injectable products in the US, the largest pharmaceutical market globally
- Leading market position in MENA (4th largest pharmaceutical company by sales) and a growing presence in Europe
- Trusted partner known for our commitment to quality and reliability of supply
2Increasingly diverse portfolio and pipeline
- Growing presence in underserved, niche areas with an increased focus on specialty and complex products, which offer less competition and potential for further margin growth
- Developing portfolio of biosimilars for the US market
- Focus on higher-value therapeutic areas such as respiratory, CNS and oncology
- Continued investment in R&D, new partnerships, strategic acquisitions and geographic expansion into certain markets
3Excellent financial discipline with a strong balance sheet and robust cash generation
- Good cash flow generation, with $638 million operating cash flow in 2021 and low leverage of 0.6x net debt/core EBITDA2
- Disciplined approach to cash management and acquisitions
- Strong balance sheet that provides financial flexibility to support future growth
4Proven track record of delivering value for shareholders and a clear vision for growth
- Group revenue CAGR of 7% and core EBITDA CAGR of 10% since 2018
- TSR3 of 313% over the last ten years
- Progressively increasing dividend
Understanding Hikma
Find out how our business model, strategy and established capabilities support our clear investment proposition
Results and presentations
Regulatory news
News feed from the London Stock Exchange's Regulatory News Service.
Download our Corporate Factsheet
Information on the high standards of governance we’re committed to, our governance structure, Board, key committees, and remuneration policy.